Jiangsu Hengrui Medicine
600276.SS
#434
Rank
NZ$95.34 B
Marketcap
NZ$14.32
Share price
-0.46%
Change (1 day)
19.43%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2025 (TTM): NZ$1.99 Billion

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings are NZ$4.19 Billion. In 2024 the company made an earning of NZ$1.73 Billion, an increase over its 2023 earnings that were of NZ$1.15 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$1.99 B14.71%
2024 NZ$1.73 B50.59%
2023 NZ$1.15 B11.35%
2022 NZ$1.03 B-13.82%
2021 NZ$1.20 B-34.16%
2020 NZ$1.82 B16.28%
2019 NZ$1.57 B32.92%
2018 NZ$1.18 B20.82%
2017 NZ$0.97 B23.8%
2016 NZ$0.79 B11.25%
2015 NZ$0.71 B39.52%
2014 NZ$0.50 B20.71%
2013 NZ$0.42 B11.46%
2012 NZ$0.37 B29.6%
2011 NZ$0.29 B31.28%
2010 NZ$0.22 B27.89%
2009 NZ$0.17 B5.84%
2008 NZ$0.16 B79.89%
2007 NZ$91.4 M32.93%
2006 NZ$68.76 M38.14%
2005 NZ$49.77 M21.56%
2004 NZ$40.95 M13.95%
2003 NZ$35.93 M38.06%
2002 NZ$26.03 M